These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 4248948)

  • 21. In vitro activity of voriconazole against dermatophytes, Scopulariopsis brevicaulis and other opportunistic fungi as agents of onychomycosis.
    Carrillo-Muñoz AJ; Giusiano G; Guarro J; Quindós G; Guardia C; del Valle O; Rodríguez V; Estivill D; Cárdenes CD
    Int J Antimicrob Agents; 2007 Aug; 30(2):157-61. PubMed ID: 17555945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro antifungal susceptibility patterns of dermatophyte strains causing tinea unguium.
    Sarifakioglu E; Seçkin D; Demirbilek M; Can F
    Clin Exp Dermatol; 2007 Nov; 32(6):675-9. PubMed ID: 17714532
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Onychomycosis in eastern Nepal.
    Agarwalla A; Agrawal S; Khanal B
    Nepal Med Coll J; 2006 Dec; 8(4):215-9. PubMed ID: 17357634
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for biofilms in onychomycosis.
    Gupta AK; Foley KA
    G Ital Dermatol Venereol; 2019 Feb; 154(1):50-55. PubMed ID: 29683287
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary report. Comparative study of pimaricin and fungicidin activity in vitro.
    Hejzlar M; Výmola F
    J Hyg Epidemiol Microbiol Immunol; 1970; 14(2):211-3. PubMed ID: 5310409
    [No Abstract]   [Full Text] [Related]  

  • 26. [Antimycotic therapy of Tinea unguium and other onychomycoses].
    Stock I
    Med Monatsschr Pharm; 2009 Aug; 32(8):289-98; quiz 299-300. PubMed ID: 19777736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The treatment of Candida skin diseases with pimaricin].
    Kejda J; Bielický T
    Mykosen; 1970 Jan; 13(1):19-24. PubMed ID: 5312332
    [No Abstract]   [Full Text] [Related]  

  • 28. Nondermatophytes. Pathogen or distracter in onychomycosis.
    Lagana FJ
    Clin Podiatr Med Surg; 1995 Apr; 12(2):255-62. PubMed ID: 7600499
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Antifungal resistance in opportunistic pathogenic fungi (II). Imidazoles and triazoles].
    Martínez-Suárez JV; Rodríguez-Tudela JL
    Enferm Infecc Microbiol Clin; 1996 Oct; 14(8):490-8. PubMed ID: 9011208
    [No Abstract]   [Full Text] [Related]  

  • 30. [Fungal flora of the nails in consideration of Trichophyton megninii].
    Krentel G
    Dermatol Monatsschr; 1970; 156(6):627-34. PubMed ID: 4252393
    [No Abstract]   [Full Text] [Related]  

  • 31. [Nail susceptibility to fungal infections in patients with hypothyroidism and hyperthyroidism].
    Macura AB; Gasińska T; Pawlik B
    Przegl Lek; 2005; 62(4):218-21. PubMed ID: 16229238
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ocular fungal isolates and antifungal susceptibility in northern China.
    Xuguang S; Zhixin W; Zhiqun W; Shiyun L; Ran L
    Am J Ophthalmol; 2007 Jan; 143(1):131-133. PubMed ID: 17188047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro susceptibility of non-Aspergillus allergenic fungal species to azoles.
    Duddy NE; Moore CB; Howard SJ; Denning DW
    J Antimicrob Chemother; 2009 Apr; 63(4):834-6. PubMed ID: 19221103
    [No Abstract]   [Full Text] [Related]  

  • 34. Onychomycosis in João Pessoa City, Brazil.
    Pontes ZB; Lima Ede O; Oliveira NM; Dos Santos JP; Ramos AL; Carvalho MF
    Rev Argent Microbiol; 2002; 34(2):95-9. PubMed ID: 12180263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A guide for the determination of resistance to antimycotics].
    Dermoumi H
    Mycoses; 1988 Oct; 31(10):532. PubMed ID: 3216877
    [No Abstract]   [Full Text] [Related]  

  • 36. Antifungal susceptibility of non-albicans Candida species causing fingernail onychomycosis.
    Upton A; Rogers K; Wood N; Morris AJ
    N Z Med J; 2004 Sep; 117(1201):U1060. PubMed ID: 15476017
    [No Abstract]   [Full Text] [Related]  

  • 37. Antifungal activity of glutaraldehyde in vitro.
    Dabrowa N; Landau JW; Newcomer VD
    Arch Dermatol; 1972 Apr; 105(4):555-7. PubMed ID: 4259594
    [No Abstract]   [Full Text] [Related]  

  • 38. [Has a decade of standardizing antifungal sensitivity tests accomplished anything?].
    Rodríguez Tudela JL; Cuenca Estrella M
    Enferm Infecc Microbiol Clin; 2002 May; 20(5):191-3. PubMed ID: 12006254
    [No Abstract]   [Full Text] [Related]  

  • 39. [Epidemiology and management of onychomycosis in private dermatological practice in France].
    Guibal F; Baran R; Duhard E; Feuilhade de Chauvin M
    Ann Dermatol Venereol; 2008; 135(8-9):561-6. PubMed ID: 18789289
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Onychomycosis due to Aspergillus candidus: case report.
    Cornere BM; Eastman M
    N Z Med J; 1975 Jul; 82(543):13-5. PubMed ID: 125865
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.